Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:41:03 ON 22 DEC 2007

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:41:20 ON 22 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 21 Dec 2007 (20071221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> nucleic (w) acid
        206347 NUCLEIC
            14 NUCLEICS
        206350 NUCLEIC
                  (NUCLEIC OR NUCLEICS)
       4501656 ACID
       1606641 ACIDS
       5007927 ACID
                  (ACID OR ACIDS)
L1      205273 NUCLEIC (W) ACID

=> HCV

         13366 HCV
            24 HCVS
L2       13370 HCV
                  (HCV OR HCVS)

=> L1 and L2
L3        1004 L1 AND L2

=> vector
        177472 VECTOR
        114886 VECTORS
```

```
L4       242586 VECTOR
                  (VECTOR OR VECTORS)

=> plasmid
         129629 PLASMID
          50609 PLASMIDS
L5       145562 PLASMID
                  (PLASMID OR PLASMIDS)

=> L2 and L4
L6          871 L2 AND L4

=> L2 and L5
L7          689 L2 AND L5

=> NS5b and L7
            924 NS5B
L8           52 NS5B AND L7

=> Ns3 and L8
           2859 NS3
L9           31 NS3 AND L8

=> NS4 and L9
            727 NS4
L10            8 NS4 AND L9

=> NS5b and L6
            924 NS5B
L11          74 NS5B AND L6

=> NS3 and L11
           2859 NS3
L12          46 NS3 AND L11

=> NS4 and L12
            727 NS4
L13          10 NS4 AND L12

=> D L10 IBIB ABS 1-8

L10  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:1334675  CAPLUS
TITLE:                    Compositions comprising the hepatitis C virus (
                          HCV) polyprotein NS3/NS4
                          and protein NS5b, recombinant expression and
                          sequences thereof, and vaccine uses
INVENTOR(S):              Inchauspe, Genevieve; Fournillier, Anne
PATENT ASSIGNEE(S):       Transgene S.A., Fr.
SOURCE:                   U.S. Pat. Appl. Publ., 75pp., Cont.-in-part of U.S.
                          Ser. No. 559,431.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2007269460         A1    20071122    US 2007-723638          20070321
     FR 2855758            A1    20041210    FR 2003-6772            20030605
     FR 2855758            B1    20050722
     WO 2004111082         A2    20041223    WO 2004-FR50214         20040604
     WO 2004111082         A3    20050217
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006134065	A1	20060622	US 2005-559431	20051205
PRIORITY APPLN. INFO.:			FR 2003-6772	A 20030605
			WO 2004-FR50214	W 20040604
			US 2005-559431	A2 20051205

AB The invention provides a compound containing a polyprotein NS3/NS4 and a polypeptide NS5b of hepatitis C virus (HCV), which has an immunogenic and protective power superior to that obtained with a vaccine addnl. including the protein NS5a and/or other structural proteins of HCV. Said invention also relates to expression vectors, such as adenovirus and poxvirus vectors, encoding the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.

L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2006:333454 CAPLUS
DOCUMENT NUMBER:	144:357638
TITLE:	Application of a transgenic mouse model of hepatitis c virus (HCV) infection and identification of antiviral agent for HCV therapeutics
INVENTOR(S):	Sallberg, Matti; Frelin, Lars
PATENT ASSIGNEE(S):	Tripep AB, Swed.
SOURCE:	PCT Int. Appl., 165 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021896	A2	20060302	WO 2005-IB3736	20050826
WO 2006021896	A3	20060817		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1781690	A2	20070509	EP 2005-810181	20050826

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

WO 2006109196	A2	20061019	WO 2006-IB1668	20060203
WO 2006109196	A3	20070315		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-605030P	P	20040827
US 2005-649975P	P	20050204
WO 2005-IB3736	W	20050826
US 2005-740362P	P	20051128

AB Disclosed herein is the discovery of novel NS3/4A compns. with enhanced expression abilities. Embodiments of the invention include codon optimized NS3/4A compns. and compns. with the Semliki forest virus replicon. Addnl. embodiments include transgenic organisms containing these NS3/4A compns., methods of using these transgenic mice to screen and refine drugs, and the drugs refined by these methods. Addnl. embodiments include protease activity dependent mols. that can indicate the presence or absence of a protease inhibitor.

L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:303181 CAPLUS
DOCUMENT NUMBER: 142:372468
TITLE: HCV fusion proteins with modified NS3 domains and uses thereof as immunogens
INVENTOR(S): Houghton, Michael
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 721,479.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005074465	A1	20050407	US 2003-612884	20030702
US 6986892	B1	20060117	US 2000-721479	20001122
US 2006057164	A1	20060316	US 2005-195009	20050802
JP 2006265267	A	20061005	JP 2006-174595	20060623

PRIORITY APPLN. INFO.:

US 1999-167502P	P	19991124
US 2000-721479	A2	20001122
US 2002-393694P	P	20020702
US 2002-394510P	P	20020708
JP 2004-519849	A3	20030702

AB The disclosed invention provides hepatitis C virus (HCV) fusion proteins that include a mutated NS3 protease domain, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in stimulation of a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compns., as well as to immunize a mammal against HCV . In expts. with Rhesus macaques, the immunization with plasmid DNA encoding an NS3(modified)NS4NS5aCore fusion protein led to activation of HCV-specific CD8-pos. T cells expressing interferon γ and proliferation of HCV-specific CD4-pos. T cells. Also presented is the use of alphavirus replicon particles.

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:392569 CAPLUS

DOCUMENT NUMBER: 140:390291
TITLE: Activation of HCV-specific T cells using fusion protein vaccines comprising HCV NS3, NS4, NS5a, and NS5b polypeptides
INVENTOR(S): Houghton, Michael; Coates, Steve; Selby, Mark; Paliard, Xavier
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039950	A2	20040513	WO 2003-US33610	20031024
WO 2004039950	A3	20071122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
CA 2505611	A1	20040513	CA 2003-2505611	20031024
AU 2003287188	A1	20040525	AU 2003-287188	20031024
EP 1576125	A2	20050921	EP 2003-781368	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-281341 A 20021025
WO 2003-US33610 W 20031024

AB The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion protein vaccines comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compns. containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compns., as well as to immunize a mammal against HCV.

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:908392 CAPLUS
DOCUMENT NUMBER: 138:13314
TITLE: Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection
AUTHOR(S): Himoudi, Nourredine; Abraham, Jean-Daniel; Fournillier, Anne; Lone, Yu Chun; Joubert, Aurelie; Op De Beeck, Anne; Freida, Delphinc; Lemonnier, Francois; Kieny, Marie Paule; Inchauspe, Genevieve
CORPORATE SOURCE: Unite Mixte CNRS-BioMerieux, UMR 2142, Ecole Normale Superieure, Lyon, 69364, Fr.
SOURCE: Journal of Virology (2002), 76(24), 12735-12746
CODEN: JOVIAM; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A polyepitopic CD8+-T-cell response is thought to be critical for control of hepatitis C virus (HCV) infection. Using transgenic mice, we analyzed the immunogenicity and dominance of most known HLA-A2.1 epitopes presented during infection by using vaccines that carry the potential to enter clin. trials: peptides, DNA, and recombinant adenoviruses. The vaccines capacity to induce specific cytotoxic T lymphocytes and interferon gamma-producing cells revealed that immunogenic epitopes are clustered in specific antigens. For two key antigens, flanking regions were shown to greatly enhance the scope of epitope recognition, whereas a DNA-adenovirus prime-boost vaccination strategy augmented epitope immunogenicity, even that of subdominant ones. The present study reveals a clustered organization of HCV immunogenic HLA.A2.1 epitopes and strategies to modulate their dominance.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:716438 CAPLUS
DOCUMENT NUMBER: 137:227663
TITLE: Hepatitis C virus (HCV) cDNA-based hepatocyte cell culture system for synthesis of infectious HCV, and uses for antiviral screening
INVENTOR(S): Dasgupta, Asim; Koka, Prasad S.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002072776	A2	20020919	WO 2002-US7516		20020311
WO 2002072776	A3	20040205			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2440433	A1	20020919	CA 2002-2440433		20020311
AU 2002254190	A1	20020924	AU 2002-254190		20020311
US 2002197277	A1	20021226	US 2002-96039		20020311
US 7183095	B2	20070227			
EP 1421222	A2	20040526	EP 2002-723409		20020311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004537279	T	20041216	JP 2002-571832		20020311
CN 1592794	A	20050309	CN 2002-806237		20020311
PRIORITY APPLN. INFO.:			US 2001-274709P	P	20010309
			WO 2002-US7516	W	20020311

AB The present invention presents a method of synthesizing infectious hepatitis C virus (HCV) by transfecting hepatocyte cells with a gene encoding HCV and then exposing uninfected cells to the HCV to form addnl. HCV. The invention relates to a HCV cDNA-based culture system capable of synthesis of infectious HCV in cell culture and cell-to-cell spread of the virus. The expression of T7 RNA polymerase in the cytoplasm was used to transcribe

the HCV cDNA under the T7 promoter to generate high quantities of HCV RNA. The viral RNA proved to be translated to produce viral structural (core, E1, E2 and p7) and nonstructural (NS2, NS3 , NS4A and B, NS5A and B) proteins. Viral RNA replication directed by the RNA-dependent RNA polymerase (NS5B) would then occur. Progeny virions were made and secreted into the tissue culture media, and infection of neighboring cells resulting in cell-to-cell spread of virus was demonstrated. The invention also relates to a method of measuring the level of HCV infection in a hepatocyte cell. A method for identifying a modulator of HCV activity is also presented, and a method for modulating HCV activity. The invention provides a reliable system for both genetic anal. of the viral genome and for the development of novel antiviral strategies.

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:319922 CAPLUS
DOCUMENT NUMBER: 134:325205
TITLE: Activation of HCV-specific T cells using hepatitis C virus nonstructural proteins, either alone or as fusions
INVENTOR(S): Paliard, Xavier; Houghton, Michael; Selby, Mark
PATENT ASSIGNEE(S): Chiron Corp., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030812	A2	20010503	WO 2000-US29594	20001027
WO 2001030812	A3	20020228		
WO 2001030812	A9	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2389206	A1	20010503	CA 2000-2389206	20001027
EP 1232267	A2	20020821	EP 2000-973922	20001027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003512826	T	20030408	JP 2001-533809	20001027
US 6562346	B1	20030513	US 2000-698874	20001027
US 2003170274	A1	20030911	US 2003-357619	20030203
US 7285539	B2	20071023		
US 2004057960	A1	20040325	US 2003-643679	20030818
US 2004191767	A1	20040930	US 2004-822607	20040412

PRIORITY APPLN. INFO.:		
US 1999-161713P	P	19991027
US 2000-698874	A1	20001027
WO 2000-US29594	W	20001027
US 2003-357619	A3	20030203

AB The invention provides a method of activating hepatitis C virus (HCV)- specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compns. containing the individual components of these fusions. The method can be used in model systems to develop

HCV-specific immunogenic compns., as well as to immunize a mammal against HCV.

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:113845 CAPLUS
DOCUMENT NUMBER: 130:163166
TITLE: Test vectors containing hepatitis C or human cytomegalovirus nucleic acid and indicator gene and methods for determining antiviral susceptibility and resistance and for antiviral screening
INVENTOR(S): Capon, Daniel J.; Whitcomb, Jeannette M.; Parkin, Neil T.
PATENT ASSIGNEE(S): Virologic, Inc., USA
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9906597	A1	19990211	WO 1998-US15967		19980730
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2298102	A1	19990211	CA 1998-2298102		19980730
AU 9888976	A	19990222	AU 1998-88976		19980730
EP 1012334	A1	20000628	EP 1998-940779		19980730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2001512036	T	20010821	JP 2000-505336		19980730
PRIORITY APPLN. INFO.:			US 1997-903507	A	19970730
			WO 1998-US15967	W	19980730

AB This invention provides a method for determining susceptibility for an HCV or HCMV anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell, and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a-c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a-c); at steps (b-c); or at step (c). This invention also provides a method for determining HCV or HCMV anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biol. effectiveness of a candidate HCV or HCMV anti-viral drug compound Compns. including resistance test vectors comprising a patient-derived segment comprising an HCV or HCMV gene and an indicator gene and host cells transformed with the resistance test vectors are provided.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D L13 IBIB ABS 1-13

L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:1334675 CAPLUS
TITLE: Compositions comprising the hepatitis C virus (HCV) polyprotein NS3/NS4 and protein NS5b, recombinant expression and sequences thereof, and vaccine uses
INVENTOR(S): Inchauspe, Genevieve; Fournillier, Anne
PATENT ASSIGNEE(S): Transgene S.A., Fr.
SOURCE: U.S. Pat. Appl. Publ., 75pp., Cont.-in-part of U.S. Ser. No. 559,431.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007269460	A1	20071122	US 2007-723638	20070321
FR 2855758	A1	20041210	FR 2003-6772	20030605
FR 2855758	B1	20050722		
WO 2004111082	A2	20041223	WO 2004-FR50214	20040604
WO 2004111082	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006134065	A1	20060622	US 2005-559431	20051205

PRIORITY APPLN. INFO.:			
FR 2003-6772	A	20030605	
WO 2004-FR50214	W	20040604	
US 2005-559431	A2	20051205	

AB The invention provides a compound containing a polyprotein NS3/NS4 and a polypeptide NS5b of hepatitis C virus (HCV), which has an immunogenic and protective power superior to that obtained with a vaccine addnl. including the protein NS5a and/or other structural proteins of HCV. Said invention also relates to expression vectors, such as adenovirus and poxvirus vectors, encoding the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:492228 CAPLUS
DOCUMENT NUMBER: 144:487147
TITLE: Yeast-based therapeutic vaccine vehicle for chronic hepatitis c infection
INVENTOR(S): Duke, Richard C.; Franzusoff, Alex; Haller, Aurelia; King, Thomas H.
PATENT ASSIGNEE(S): Globeimmune, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 738,646.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006110755	A1	20060525	US 2005-254252		20051018
US 2004156858	A1	20040812	US 2003-738646		20031216
			US 2002-434163P	P	20021216
			US 2003-738646	A2	20031216
			US 2004-620158P	P	20041018

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 144:487147

AB The present invention relates to compns., including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:333454 CAPLUS
DOCUMENT NUMBER: 144:357638
TITLE: Application of a transgenic mouse model of hepatitis c virus (HCV) infection and identification of antiviral agent for HCV therapeutics
INVENTOR(S): Sallberg, Matti; Frelin, Lars
PATENT ASSIGNEE(S): Tripep AB, Swed.
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021896	A2	20060302	WO 2005-IB3736	20050826
WO 2006021896	A3	20060817		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1781690	A2	20070509	EP 2005-810181	20050826
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
WO 2006109196	A2	20061019	WO 2006-IB1668	20060203
WO 2006109196	A3	20070315		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-605030P	P	20040827
US 2005-649975P	P	20050204
WO 2005-IB3736	W	20050826
US 2005-740362P	P	20051128

AB Disclosed herein is the discovery of novel NS3/4A compns. with enhanced expression abilities. Embodiments of the invention include codon optimized NS3/4A compns. and compns. with the Semliki forest virus replicon. Addnl. embodiments include transgenic organisms containing these NS3/4A compns., methods of using these transgenic mice to screen and refine drugs, and the drugs refined by these methods. Addnl. embodiments include protease activity dependent mols. that can indicate the presence or absence of a protease inhibitor.

L13 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:303181 CAPLUS
DOCUMENT NUMBER: 142:372468
TITLE: HCV fusion proteins with modified NS3 domains and uses thereof as immunogens
INVENTOR(S): Houghton, Michael
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 721,479.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005074465	A1	20050407	US 2003-612884	20030702
US 6986892	B1	20060117	US 2000-721479	20001122
US 2006057164	A1	20060316	US 2005-195009	20050802
JP 2006265267	A	20061005	JP 2006-174595	20060623

PRIORITY APPLN. INFO.:

US 1999-167502P	P	19991124
US 2000-721479	A2	20001122
US 2002-393694P	P	20020702
US 2002-394510P	P	20020708
JP 2004-519849	A3	20030702

AB The disclosed invention provides hepatitis C virus (HCV) fusion proteins that include a mutated NS3 protease domain, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in stimulation of a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compns., as well as to immunize a mammal against HCV . In expts. with Rhesus macaques, the immunization with plasmid DNA encoding an NS3(modified)NS4NS5aCore fusion protein led to activation of HCV-specific CD8-pos. T cells expressing interferon γ and proliferation of HCV-specific CD4-pos. T cells. Also presented is the use of alphavirus replicon particles.

L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:905910 CAPLUS

DOCUMENT NUMBER: 141:378844
TITLE: Inducing a T cell response with recombinant antigen-expressing pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells, and therapeutic uses
INVENTOR(S): Rehermann, Barbara; Racanelli, Vito; Behrens, Sven-Erik; Tautz, Norbert
PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of Health and Human Services, USA; Justus-Liebig-Universitaet Giessen
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092386	A2	20041028	WO 2004-US11018	20040410
WO 2004092386	A3	20050512		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-462165P P 20030411
US 2003-463097P P 20030414

AB The present disclosure relates to compds. and methods of generating T cell-mediated immunity, particularly T cell-mediated immunity to Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Human Immunodeficiency Virus (HIV), Mycobacterium tuberculosis, Plasmodium falciparum, and tumors. The method includes (a) administering to the subject an amount of an antigen presenting cell (such as dendritic cell) sufficient to induce the response in the subject, wherein the antigen presenting cell expresses the recombinant antigen from a pestivirus replicon or (b) directly administering the recombinant antigen expressing replicon in form of RNA or DNA.

L13 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:908392 CAPLUS
DOCUMENT NUMBER: 138:13314
TITLE: Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection
AUTHOR(S): Himoudi, Nourredine; Abraham, Jean-Daniel; Fournillier, Anne; Lone, Yu Chun; Joubert, Aurelie; Op De Beeck, Anne; Freida, Delphinc; Lemonnier, Francois; Kieny, Marie Paule; Inchauspe, Genevieve
CORPORATE SOURCE: Unite Mixte CNRS-BioMerieux, UMR 2142, Ecole Normale Superieure, Lyon, 69364, Fr.
SOURCE: Journal of Virology (2002), 76(24), 12735-12746
CODEN: JOVIAM; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A polyepitopic CD8+-T-cell response is thought to be critical for control of hepatitis C virus (HCV) infection. Using transgenic mice, we

analyzed the immunogenicity and dominance of most known HLA-A2.1 epitopes presented during infection by using vaccines that carry the potential to enter clin. trials: peptides, DNA, and recombinant adenoviruses. The vaccines capacity to induce specific cytotoxic T lymphocytes and interferon gamma-producing cells revealed that immunogenic epitopes are clustered in specific antigens. For two key antigens, flanking regions were shown to greatly enhance the scope of epitope recognition, whereas a DNA-adenovirus prime-boost vaccination strategy augmented epitope immunogenicity, even that of subdominant ones. The present study reveals a clustered organization of HCV immunogenic HLA.A2.1 epitopes and strategies to modulate their dominance.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:716438 CAPLUS
DOCUMENT NUMBER: 137:227663
TITLE: Hepatitis C virus (HCV) cDNA-based hepatocyte cell culture system for synthesis of infectious HCV, and uses for antiviral screening
INVENTOR(S): Dasgupta, Asim; Koka, Prasad S.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002072776	A2	20020919	WO 2002-US7516		20020311
WO 2002072776	A3	20040205			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2440433	A1	20020919	CA 2002-2440433		20020311
AU 2002254190	A1	20020924	AU 2002-254190		20020311
US 2002197277	A1	20021226	US 2002-96039		20020311
US 7183095	B2	20070227			
EP 1421222	A2	20040526	EP 2002-723409		20020311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004537279	T	20041216	JP 2002-571832		20020311
CN 1592794	A	20050309	CN 2002-806237		20020311
PRIORITY APPLN. INFO.:			US 2001-274709P	P	20010309
			WO 2002-US7516	W	20020311

AB The present invention presents a method of synthesizing infectious hepatitis C virus (HCV) by transfecting hepatocyte cells with a gene encoding HCV and then exposing uninfected cells to the HCV to form addnl. HCV. The invention relates to a HCV cDNA-based culture system capable of synthesis of infectious HCV in cell culture and cell-to-cell spread of the virus. The expression of T7 RNA polymerase in the cytoplasm was used to transcribe the HCV cDNA under the T7 promoter to generate high quantities of HCV RNA. The viral RNA proved to be translated to produce

viral structural (core, E1, E2 and p7) and nonstructural (NS2, NS3 , NS4A and B, NS5A and B) proteins. Viral RNA replication directed by the RNA-dependent RNA polymerase (NS5B) would then occur. Progeny virions were made and secreted into the tissue culture media, and infection of neighboring cells resulting in cell-to-cell spread of virus was demonstrated. The invention also relates to a method of measuring the level of HCV infection in a hepatocyte cell. A method for identifying a modulator of HCV activity is also presented, and a method for modulating HCV activity. The invention provides a reliable system for both genetic anal. of the viral genome and for the development of novel antiviral strategies.

L13 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:113845 CAPLUS
DOCUMENT NUMBER: 130:163166
TITLE: Test vectors containing hepatitis C or human cytomegalovirus nucleic acid and indicator gene and methods for determining antiviral susceptibility and resistance and for antiviral screening
INVENTOR(S): Capon, Daniel J.; Whitcomb, Jeannette M.; Parkin, Neil T.
PATENT ASSIGNEE(S): Virologic, Inc., USA
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9906597	A1	19990211	WO 1998-US15967		19980730
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2298102	A1	19990211	CA 1998-2298102		19980730
AU 9888976	A	19990222	AU 1998-88976		19980730
EP 1012334	A1	20000628	EP 1998-940779		19980730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2001512036	T	20010821	JP 2000-505336		19980730
PRIORITY APPLN. INFO.:			US 1997-903507	A	19970730
			WO 1998-US15967	W	19980730

AB This invention provides a method for determining susceptibility for an HCV or HCMV anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell, and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a-c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a-c); at steps (b-c); or at step (c). This invention also provides a method for determining HCV or HCMV anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the

anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biol. effectiveness of a candidate HCV or HCMV anti-viral drug compound Compns. including resistance test vectors comprising a patient-derived segment comprising an HCV or HCMV gene and an indicator gene and host cells transformed with the resistance test vectors are provided.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:251284 CAPLUS
DOCUMENT NUMBER: 128:292153
TITLE: Protease regulator screening assay using a recombinant polypeptide comprising anchor, protease recognition, and signal regions
INVENTOR(S): Chien, David Y.; Selby, Mark J.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816657	A1	19980423	WO 1997-US18632	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749043	A	19980511	AU 1997-49043	19971017
US 6436666	B1	20020820	US 1997-997055	19971017
US 2003113825	A1	20030619	US 2002-225390	20020820
US 6924122	B2	20050802		
US 2006292659	A1	20061228	US 2005-193615	20050801

PRIORITY APPLN. INFO.:

US 1996-28817P	P	19961017
US 1997-997055	A1	19971017
WO 1997-US18632	W	19971017
US 2002-225390	A3	20020820

AB A polypeptide containing an anchor region, a protease recognition site, and a detectable signal region can be produced recombinantly and directly attached to a solid support. The polypeptide is useful for screening protease regulators, especially protease inhibitors. Thus, a recombinant protein is produced in which the anchor region is protein A which specifically binds to an antibody, the protease recognition site is that for hepatitis C virus NS3 protease such as that for NS4A/NS4B or HS4B/NS5A cleavage, and the signal region comprises the epitope FLAG sequence. A fragment encoding HCV NS5 peptide protease target site is inserted in frame into the polylinker region of pEZZ18 so that it is connected at the C-terminal region of protein A. The NS5 peptide protease target site includes the NS5A and NS5B cleavage site, i.e., amino acids 2420 and 2421, 7 amino acids at the N-terminal side of the cleavage site, and 8 amino acids at the C-terminal side of the cleavage site. Another sequence fragment encoding the FLAG tag is inserted in frame at the C-terminal end of the NS5 protease target site. The sequence fragment encodes three FLAG tags alternately spaced with two

4-glycine spacers. The assay is readily adapted to an automated format and is suitable for large scale drug screens, as demonstrated by screening for potentially therapeutically useful inhibitors of the HCV protease.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:228414 CAPLUS
DOCUMENT NUMBER: 126:247257
TITLE: Hepatitis C virus (HCV) RNA polymerase assay using cloned HCV non-structural proteins
AUTHOR(S): Bartholomeusz, Angeline I.; Guo, Ke-Jian; Edwards, Patrick C.; Locarnini, Stephen A.
CORPORATE SOURCE: Victorian Infectious Diseases Reference Laboratory, Victoria, 3078, Australia
SOURCE: Antiviral Therapy (1996), 1(Suppl. 4, Therapies for Viral Hepatitis), 18-24
CODEN: ANTHFA; ISSN: 1359-6535
PUBLISHER: International Medical Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Investigations into the RNA replication of hepatitis C virus (HCV) have been hampered by the lack of a cell-culture system. The objective of this study was to develop an in vitro system to study HCV polymerase activity and RNA replication. We are currently developing two HCV RNA replication assays. The first reconstitutes the various components required for RNA synthesis: cloned viral non-structural proteins as the source of the viral polymerase and helicase, exts. from uninfected Vero (African green monkey kidney) or HepG2 (human hepatoma) cells as the source of host factors and an RNA template (either HCV RNA transcripts or RNA from the pestivirus bovine viral diarrhea virus). The second assay uses HCV-infected liver cell exts. and thus contains authentic replication complexes consisting of viral and host proteins and RNA templates. In both assays, synthesis of viral RNA is detected by the incorporation of the radiolabel [α-32P]GTP. In the assay using cloned viral protein, the genes encoding NS2, NS3, NS4, NS5A and NS5B from pBRTM/HCV 1-3011 were cloned into the transcription vector pT7T3. The transcribed RNA was translated with rabbit reticulocytes in the presence of canine pancreatic membranes. Radiolabeled RNA was detected only in polymerase assays that contained the translated proteins and all other components. In assays using infected liver cell exts., radiolabel was incorporated into RNA products that were not present in control assays using uninfected liver cell exts. Both assays will be useful in the elucidation of processes involved in HCV RNA replication and in the development of antiviral agents.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	76.81	77.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.04	-14.04

FILE 'STNGUIDE' ENTERED AT 17:46:25 ON 22 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 18, 2007 (20071218/UP).